Generation Bio Co.

NasdaqGS:GBIO Stock Report

Market Cap: US$79.5m

Generation Bio Management

Management criteria checks 3/4

Generation Bio's CEO is Geoff McDonough, appointed in Oct 2017, has a tenure of 7.17 years. total yearly compensation is $2.32M, comprised of 27.2% salary and 72.8% bonuses, including company stock and options. directly owns 2.75% of the company’s shares, worth $2.19M. The average tenure of the management team and the board of directors is 3.6 years and 7 years respectively.

Key information

Geoff McDonough

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage27.2%
CEO tenure7.2yrs
CEO ownership2.8%
Management average tenure3.6yrs
Board average tenure7yrs

Recent management updates

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

CEO Compensation Analysis

How has Geoff McDonough's remuneration changed compared to Generation Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$145m

Jun 30 2024n/an/a

-US$158m

Mar 31 2024n/an/a

-US$169m

Dec 31 2023US$2mUS$630k

-US$127m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$134m

Dec 31 2022US$4mUS$606k

-US$137m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$129m

Dec 31 2021US$6mUS$583k

-US$119m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$101m

Mar 31 2021n/an/a

-US$88m

Dec 31 2020US$2mUS$516k

-US$81m

Sep 30 2020n/an/a

-US$72m

Jun 30 2020n/an/a

-US$68m

Mar 31 2020n/an/a

-US$65m

Dec 31 2019US$593kUS$424k

-US$61m

Compensation vs Market: Geoff's total compensation ($USD2.32M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Geoff's compensation has been consistent with company performance over the past year.

CEO

Geoff McDonough (54 yo)

7.2yrs

Tenure

US$2,315,263

Compensation

Dr. Cameron Geoffrey McDonough, also known as Geoff, M.D. serves as Independent Director of Third Harmonic Bio, Inc. since March 2024. He had been an Independent Director of Surface Oncology, Inc. since Fe...

Leadership Team

NamePositionTenureCompensationOwnership
Cameron McDonough
President7.2yrsUS$2.32m2.75%
$ 2.2m
Matthew Norkunas
Chief Financial Officer4.4yrsUS$1.14m0.086%
$ 68.2k
Matthew Stanton
Chief Scientific Officer5.6yrsUS$1.15m0.37%
$ 294.3k
Yalonda Howze
Chief Legal Officer & Secretary1.7yrsUS$1.21m0.021%
$ 16.9k
Mark Angelino
Co-Founder8.2yrsno datano data
Robert Kotin
Co-Founderno datano datano data
Antoinette Paone
Chief Operating Officer2.8yrsno data0.024%
$ 19.1k
Jasmin Tower
Chief Human Resources Officer1.8yrsno datano data
Phillip Samayoa
Chief Strategy Officer2.3yrsno data0.18%
$ 145.3k

3.6yrs

Average Tenure

51yo

Average Age

Experienced Management: GBIO's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cameron McDonough
President7.2yrsUS$2.32m2.75%
$ 2.2m
Jason Rhodes
Independent Chairman7.2yrsUS$181.21k0%
$ 0
Gustav Christensen
Independent Director7yrsUS$143.71k0.20%
$ 156.4k
Charles Rowland
Independent Director6.4yrsUS$151.21k0.80%
$ 636.4k
Anthony Quinn
Independent Director7yrsUS$143.71k0.24%
$ 192.0k
Andrew Scharenberg
Chairman of Scientific Advisory Boardno datano datano data
Donald Nicholson
Independent Director7yrsUS$143.71k0.32%
$ 254.2k
Kevin Fitzgerald
Member of Scientific Advisory Boardno datano datano data
Adrian Thrasher
Member of Scientific Advisory Boardno datano datano data
Ronald H. Cooper
Independent Director3.8yrsUS$144.21k0.014%
$ 11.3k
Catherine Stehman-Breen
Independent Director7yrsUS$143.71k0.071%
$ 56.6k
Richard Thompson
Member of Scientific Advisory Board6.2yrsno datano data

7.0yrs

Average Tenure

61yo

Average Age

Experienced Board: GBIO's board of directors are considered experienced (7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:26
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Generation Bio Co. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Eun Kyung YangJefferies LLC
Farzin HaqueJefferies LLC